Journal
ONCOLOGIST
Volume 8, Issue 1, Pages 5-17Publisher
WILEY
DOI: 10.1634/theoncologist.8-1-5
Keywords
breast neoplasm; biologic therapy; prognostic markers; IGF-IR; EGFR; HER2; monoclonal antibodies; tyrosine kinase inhibitors
Categories
Funding
- NATIONAL CANCER INSTITUTE [K23CA082119] Funding Source: NIH RePORTER
- NCI NIH HHS [K23 CA82119] Funding Source: Medline
Ask authors/readers for more resources
Increased expression and activation of receptor tyrosine kinases occurs frequently in human breast carcinomas. Several therapies targeting these receptors are currently in clinical trials. Therapeutic strategies include blockade of individual receptors with monoclonal antibodies and inhibition of tyrosine kinase function. Trastuzumab is the first of these biologic therapies to be approved for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic breast cancer. Novel trastuzumab-based combinations are being investigated in patients with advanced breast cancer. Large clinical trials have also been launched in the adjuvant setting. Small molecules that inhibit specific tyrosine kinases (e.g., epidermal growth factor receptor, HER2) are in phase I and phase II clinical trials. Other growth-factor-targeted drugs that have reached clinical development include STI571 and antibodies directed at the insulin-like growth factor pathway. Biologic therapies directed against these important receptors are promising. In this review we discuss challenges and opportunities for the development of growth-factor-targeted approaches for the treatment of breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available